α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma

Acta Biomater. 2018 Aug;76:193-207. doi: 10.1016/j.actbio.2018.06.029. Epub 2018 Jun 22.

Abstract

α-Galactosylceramide (GalCer) is a glycolipid widely known as an activator of Natural killer T (NKT) cells, constituting a promising adjuvant against cancer, including melanoma. However, limited clinical outcomes have been obtained so far. This study evaluated the synergy between GalCer and major histocompatibility complex (MHC) class I and MHC class II melanoma-associated peptide antigens and the Toll-Like Receptor (TLR) ligands CpG and monophosphoryl lipid A (MPLA), which we intended to maximize following their co-delivery by a nanoparticle (NP). This is expected to improve GalCer capture by dendritic cells (DCs) and subsequent presentation to NKT cells, simultaneously inducing an anti-tumor specific T-cell mediated immunity. The combination of GalCer with melanoma peptides and TLR ligands successfully restrained tumor growth. The tumor volume in these animals was 5-fold lower than the ones presented by mice immunized with NPs not containing GalCer. However, tumor growth was controlled at similar levels by GalCer entrapped or in its soluble form, when mixed with antigens and TLR ligands. Those two groups showed an improved infiltration of T lymphocytes into the tumor, but only GalCer-loaded nano-vaccine induced a prominent and enhanced infiltration of NKT and NK cells. In addition, splenocytes of these animals secreted levels of IFN-γ and IL-4 at least 1.5-fold and 2-fold higher, respectively, than those treated with the mixture of antigens and adjuvants in solution. Overall, the combined delivery of the NKT agonist with TLR ligands and melanoma antigens via this multivalent nano-vaccine displayed a synergistic anti-tumor immune-mediated efficacy in B16F10 melanoma mouse model.

Statement of significance: Combination of α-galactosylceramide (GalCer), a Natural Killer T (NKT) cell agonist, with melanoma-associated antigens presented by MHC class I (Melan-A:26) and MHC class II (gp100:44) molecules, and Toll-like Receptor (TLR) ligands (MPLA and CpG), within nanoparticle matrix induced a prominent anti-tumor immune response able to restrict melanoma growth. An enhanced infiltration of NKT and NK cells into tumor site was only achieved when the combination GalCer, antigens and TLR ligands were co-delivered by the nanovaccine.

Keywords: Melanoma; Nanoparticles; Natural killer T cells; Toll-like receptor ligands; α-Galactosylceramide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer Vaccines* / chemistry
  • Cancer Vaccines* / pharmacokinetics
  • Cancer Vaccines* / pharmacology
  • Cell Line, Tumor
  • Dendritic Cells / immunology
  • Dendritic Cells / pathology
  • Galactosylceramides* / chemistry
  • Galactosylceramides* / pharmacokinetics
  • Galactosylceramides* / pharmacology
  • Immunity, Cellular / drug effects*
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / pathology
  • Male
  • Melanoma, Experimental / immunology
  • Melanoma, Experimental / pathology
  • Melanoma, Experimental / therapy*
  • Mice
  • Mice, Inbred C57BL
  • Nanoparticles* / chemistry
  • Nanoparticles* / therapeutic use
  • Peptides* / chemistry
  • Peptides* / pharmacokinetics
  • Peptides* / pharmacology
  • T-Lymphocytes / immunology
  • T-Lymphocytes / pathology
  • Toll-Like Receptors / immunology

Substances

  • Cancer Vaccines
  • Galactosylceramides
  • Peptides
  • Toll-Like Receptors
  • alpha-galactosylceramide